Skip to search formSkip to main contentSkip to account menu

CDK4/6 Inhibition

Known as: Cyclin-Dependent Kinases 4 and 6 Inhibition 
Inhibition of cyclin-dependent kinases 4 and 6 pathway activity to prevent proliferation of cancer cells and tumor growth.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
PAK1 silencing is synthetic lethal with CDK4/6 inhibition in gastric cancer cells via regulating PDK1 expression
Gastric cancer (GC) is one of the most common malignancies worldwide. The prognosis of GC is unsatisfied owning to widespread… 
2019
2019
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer
Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib and abemaciclib) and mammalian target of rapamycin (mTOR… 
2019
2019
Abstract 1322: Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors driven by aberrant RAS-MAPK signaling
SHP2 (PTPN11) is a protein tyrosine phosphatase and scaffold protein that functions as a convergent node downstream of multiple… 
2018
2018
Abstract PD4-03: CDK4/6 inhibition blocks effects of IGFs and insulin in estrogen receptor positive and triple negative breast cancers: Implications for cotargeting IGF1R/IR and CDKs
IGF and insulin signaling via the type I insulin-like growth factor receptor (IGF1R) and insulin receptor (IR) respectively, are… 
2018
2018
Abstract B04: CDK4/6 inhibition triggers an antitumor immune response
Introduction: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have demonstrated significant efficacy in clinical trials in a… 
2017
2017
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
Resistance to second-generation androgen receptor (AR) antagonists and CYP17 inhibitors in patients with castration-resistant… 
2017
2017
Abstract 2344: Beyond RB1: the pocket protein p130 mediates the effects of CDK4/6 inhibition in RB1-deficient urothelial carcinoma
Introduction: Urothelial carcinoma is characterized by a high incidence of molecular alterations in the CDKN2A-RB-E2F axis. Loss… 
2017
2017
Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer
The use of CDK inhibitors (palbociclib, ribociclib, abemaciclib) for patients with metastatic ER-positive breast cancer has been… 
2016
2016
Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel
Among patients with hormone receptor (HR)-positive breast cancer, those with residual disease after neoadjuvant chemotherapy have… 
2016
2016
Abstract A73: CDK4/6 inhibition as maintenance therapy in ovarian cancer.
Over 70% of patients with ovarian cancer who achieve a clinical remission with initial surgery and chemotherapy will relapse and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)